JP2022545920A5 - - Google Patents
Info
- Publication number
- JP2022545920A5 JP2022545920A5 JP2022513208A JP2022513208A JP2022545920A5 JP 2022545920 A5 JP2022545920 A5 JP 2022545920A5 JP 2022513208 A JP2022513208 A JP 2022513208A JP 2022513208 A JP2022513208 A JP 2022513208A JP 2022545920 A5 JP2022545920 A5 JP 2022545920A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- single dose
- antibody
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025129247A JP2025185263A (ja) | 2019-08-29 | 2025-08-01 | Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893742P | 2019-08-29 | 2019-08-29 | |
| US62/893,742 | 2019-08-29 | ||
| PCT/US2020/048649 WO2021042000A1 (en) | 2019-08-29 | 2020-08-28 | Antibody compositions and methods for treating hepatitis b virus infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025129247A Division JP2025185263A (ja) | 2019-08-29 | 2025-08-01 | Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022545920A JP2022545920A (ja) | 2022-11-01 |
| JP2022545920A5 true JP2022545920A5 (https=) | 2023-08-31 |
Family
ID=72473989
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513208A Pending JP2022545920A (ja) | 2019-08-29 | 2020-08-28 | Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法 |
| JP2025129247A Pending JP2025185263A (ja) | 2019-08-29 | 2025-08-01 | Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025129247A Pending JP2025185263A (ja) | 2019-08-29 | 2025-08-01 | Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220380441A1 (https=) |
| EP (1) | EP4021578A1 (https=) |
| JP (2) | JP2022545920A (https=) |
| KR (1) | KR20220063188A (https=) |
| CN (1) | CN114630680B (https=) |
| AU (1) | AU2020336980B2 (https=) |
| BR (1) | BR112022003698A2 (https=) |
| CA (1) | CA3152511A1 (https=) |
| IL (1) | IL290923A (https=) |
| MX (1) | MX2022002231A (https=) |
| WO (1) | WO2021042000A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3898668T3 (fi) | 2018-12-19 | 2023-11-28 | Humabs Biomed Sa | B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä |
| RS67553B1 (sr) | 2018-12-20 | 2026-01-30 | Humabs Biomed Sa | Kombinovana hbv terapija |
| JP2024504167A (ja) * | 2021-01-26 | 2024-01-30 | ヴィア・バイオテクノロジー・インコーポレイテッド | Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法 |
| TW202411246A (zh) * | 2022-05-23 | 2024-03-16 | 美商維爾生物科技股份有限公司 | 經工程化之b型肝炎病毒中和抗體及其用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP2158318A2 (en) | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| PL2350128T3 (pl) | 2008-10-22 | 2015-03-31 | Inst Res Biomedicine | Sposoby wytwarzania przeciwciał z komórek plazmatycznych |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| CA2894879A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| WO2016040724A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| DK3653221T5 (da) | 2015-02-19 | 2024-08-26 | Compugen Ltd | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| CN117924477A (zh) * | 2017-12-19 | 2024-04-26 | 洛克菲勒大学 | 具有改进的效应子功能的人IgG Fc结构域变体 |
| FI3898668T3 (fi) * | 2018-12-19 | 2023-11-28 | Humabs Biomed Sa | B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä |
| RS67553B1 (sr) * | 2018-12-20 | 2026-01-30 | Humabs Biomed Sa | Kombinovana hbv terapija |
-
2020
- 2020-08-28 CA CA3152511A patent/CA3152511A1/en active Pending
- 2020-08-28 CN CN202080075610.1A patent/CN114630680B/zh active Active
- 2020-08-28 AU AU2020336980A patent/AU2020336980B2/en active Active
- 2020-08-28 US US17/637,605 patent/US20220380441A1/en active Pending
- 2020-08-28 KR KR1020227010266A patent/KR20220063188A/ko active Pending
- 2020-08-28 BR BR112022003698A patent/BR112022003698A2/pt unknown
- 2020-08-28 MX MX2022002231A patent/MX2022002231A/es unknown
- 2020-08-28 WO PCT/US2020/048649 patent/WO2021042000A1/en not_active Ceased
- 2020-08-28 JP JP2022513208A patent/JP2022545920A/ja active Pending
- 2020-08-28 EP EP20771699.4A patent/EP4021578A1/en active Pending
-
2022
- 2022-02-27 IL IL290923A patent/IL290923A/en unknown
-
2025
- 2025-08-01 JP JP2025129247A patent/JP2025185263A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022545920A5 (https=) | ||
| Lok | Treatment of chronic hepatitis B | |
| Qaqish et al. | Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection | |
| TWI732156B (zh) | 用於治療和/或預防與肝炎病毒相關的疾病或病症的雙二氮雜雙環化合物 | |
| JP2022532211A5 (https=) | ||
| CN115920061A (zh) | Hbv和hdv感染的联合治疗 | |
| KR20220119616A (ko) | Tlr7 효현제를 이용하여 바이러스 감염을 치료하는 방법 | |
| Kim et al. | Telbivudine: a novel nucleoside analog for chronic hepatitis B | |
| Lau | Hepatitis B infection in China | |
| JP2002534438A (ja) | 新規治療法 | |
| JP2025511096A5 (https=) | ||
| AU2020314081B2 (en) | Synergistic effect of EYP001 and IFN for the treatment of HBV infection | |
| NZ785788B2 (en) | Antibody compositions and methods for treating hepatitis b virus infection | |
| NZ785788A (en) | Antibody compositions and methods for treating hepatitis b virus infection | |
| KR20120125253A (ko) | Ｂ형 간염 바이러스 감염 치료용 조성물 및 치료방법 | |
| Zuccotti et al. | A 1-year trial of lamivudine for chronic hepatitis B in children | |
| KR20220098345A (ko) | 바이러스성 간염을 치료 또는 예방하기 위한 약물 조성물 및 그의 응용 | |
| Çakir et al. | Successful treatment with adefovir of one patient whose cryoglobulinemic vasculitis relapsed under lamivudine therapy and who was diagnosed to have HBV virologic breakthrough with YMDD mutations | |
| WO2008104133A1 (es) | Terapia combinada para el tratamiento de la hepatitis b crónica | |
| CN112891510A (zh) | 采用iap抑制剂的治疗方法 | |
| HK40044248A (en) | Treatment method with iap inhibitor | |
| Bhatnagar | 34 Chronic Hepatitis B | |
| HK40088755A (zh) | Hbv和hdv感染的联合治疗 | |
| Korkmaz et al. | Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients | |
| HK40066536B (en) | Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection |